BCR and B-cell chronic lymphocytic leukemia: As IB does not influence eEF2K/eEF2 signalling or protein synthesis in primary CLL cells, our results suggest that a combination of IB with nelfinavir to target both BCR-mediated signalling and translation elongation may provide enhanced clinical benefit to CLL patients.